- Home
- IMUX vs SGA Comparison
IMUX vs SGA Comparison
Compare IMUX & SGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMUX | SGA |
|---|---|---|
| Founded | 2016 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Broadcasting |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.2M | 72.1M |
| IPO Year | N/A | 1992 |
Fundamental Metrics
Financial Performance| Metric | IMUX | SGA |
|---|---|---|
| Price | $0.70 | $11.37 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 7.7K |
| Earning Date | 02-26-2026 | 03-10-2026 |
| Dividend Yield | N/A | ★ 8.83% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.05 |
| Revenue | N/A | ★ $109,822,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.53 |
| P/E Ratio | ★ N/A | $237.20 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.51 | $10.68 |
| 52 Week High | $1.39 | $14.27 |
Technical Indicators
Market Signals| Indicator | IMUX | SGA |
|---|---|---|
| Relative Strength Index (RSI) | 59.00 | 53.29 |
| Support Level | $0.57 | $11.20 |
| Resistance Level | $0.69 | $11.50 |
| Average True Range (ATR) | 0.06 | 0.20 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 85.40 | 95.43 |
Price Performance
Historical ComparisonAbout IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
About SGA Saga Communications Inc. (FL)
Saga Communications Inc is a broadcast company engaged in acquiring, developing, and operating broadcast properties. The company's objective is to operate top billing radio stations in mid-sized markets. It derives a majority of its revenue from the sale of advertising for broadcast on its stations.